---
title: "Liaoning He Eye Hospital Group Co.,Ltd. (301103.SZ)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/301103.SZ.md"
symbol: "301103.SZ"
name: "Liaoning He Eye Hospital Group Co.,Ltd."
industry: "Health Care Services"
datetime: "2026-05-21T09:22:07.315Z"
locales:
  - [en](https://longbridge.com/en/quote/301103.SZ.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/301103.SZ.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/301103.SZ.md)
---

# Liaoning He Eye Hospital Group Co.,Ltd. (301103.SZ)

## Company Overview

Liaoning He Eye Hospital Group Co., LTD. provides ophthalmic specialist diagnosis, treatment, and optometry services to patients with eye diseases. It offers cataract diagnosis and treatment, refractive error surgical correction, vitreoretinal diagnosis and treatment, other surgical diagnosis and treatment services, etc. The company also provides refractive cataracts, LASIK surgery, myopia prevention, medical fitting, diabetic retinopathy, dry eyes and cornea, gene diagnosis, and comprehensive eye disease solutions.

| Item | Detail |
|------|--------|
| Industry | Health Care Services |
| Exchange | CN Market |
| Website | [www.hsyk.com.cn](https://www.hsyk.com.cn) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: B
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-21T04:30:14.000Z

**Overall: B (0.39)**

**Industry**: Health Care Services

| Metric | Value |
|--------|-------|
| Industry Ranking | 2 / 8 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: B

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 0.36% |  |
| Net Profit YoY | 215.31% |  |
| P/B Ratio | 1.54 |  |
| Dividend Ratio | 0.79% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 2949414134.17 |  |
| Revenue | 1104200711.40 |  |

#### Multi Score Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 1.43% | D |
| Profit Margin | 2.49% | C |
| Gross Margin | 44.24% | B |
| Revenue YoY | 0.36% | C |
| Net Profit YoY | 215.31% | A |
| Total Assets YoY | -1.33% | D |
| Net Assets YoY | 0.51% | C |
| Cash Flow Margin | 556.74% | A |
| OCF YoY | 0.36% | C |
| Turnover | 0.49 | C |
| Gearing Ratio | 13.94% | A |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Liaoning He Eye Hospital Group Co.,Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "0.36%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "215.31%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "1.54",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.79%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "2949414134.17",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "1104200711.40",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "1.43%",
          "rating": "D"
        },
        {
          "name": "Profit Margin",
          "value": "2.49%",
          "rating": "C"
        },
        {
          "name": "Gross Margin",
          "value": "44.24%",
          "rating": "B"
        },
        {
          "name": "Revenue YoY",
          "value": "0.36%",
          "rating": "C"
        },
        {
          "name": "Net Profit YoY",
          "value": "215.31%",
          "rating": "A"
        },
        {
          "name": "Total Assets YoY",
          "value": "-1.33%",
          "rating": "D"
        },
        {
          "name": "Net Assets YoY",
          "value": "0.51%",
          "rating": "C"
        },
        {
          "name": "Cash Flow Margin",
          "value": "556.74%",
          "rating": "A"
        },
        {
          "name": "OCF YoY",
          "value": "0.36%",
          "rating": "C"
        },
        {
          "name": "Turnover",
          "value": "0.49",
          "rating": "C"
        },
        {
          "name": "Gearing Ratio",
          "value": "13.94%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 107.48 | 5/8 | 319.87 | 301.42 | 285.65 |
| PB | 1.54 | 2/8 | 1.83 | 1.76 | 1.64 |
| PS (TTM) | 2.67 | 5/8 | 3.21 | 3.08 | 2.87 |
| Dividend Yield | 0.79% | 5/8 | 0.76% | 0.71% | 0.67% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | TC Medical (600763.SH) | B | C | C | B | C | B |
| 02 | HESH (301103.SZ) | C | C | C | A | B | B |
| 03 | Meinian Onehealth (002044.SZ) | C | D | C | C | B | C |
| 04 | Kingmed Diagnostics (603882.SH) | D | D | B | B | E | C |
| 05 | Dian Diagnostics (300244.SZ) | C | D | B | B | C | C |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/301103.SZ/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/301103.SZ/norm.md)
- [Related News](https://longbridge.com/en/quote/301103.SZ/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/301103.SZ/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**